nach oben

vorheriger Artikel American Society of Hematology 2016 annual meeting

nächster Artikel News in AL Amyloidosis ASH 2016

Tipp

Hematopoietic stem cell transplantation: up-date from ASH 2016

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 2/2017

Autor:: MD Georg Hopfinger

Summary

Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70. CrossRefPubMed

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. CrossRefPubMedPubMedCentral

Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66. CrossRefPubMed

Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. CrossRefPubMedPubMedCentral

Jaksch M, Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 2005;61(5):398–409. CrossRefPubMed

Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21–e9. CrossRefPubMedPubMedCentral

Hartwell M, Ozbek U, Holler E, Renteria A, Reddy P, Aziz M, et al. An early biomarker algorithm predicts lethal graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation. Blood. 2016;128(22):abstr 509.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–8. PubMedPubMedCentral

Miklos D, Cutler S, Arora M, Waller EK, Jagasia M, Pusic I, et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. Blood. 2016;128(22):abstr LBA-3.

10.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):e427–e36. CrossRefPubMed

11.

Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035–44. CrossRefPubMed

12.

Scott BLP, Logan B, Wu J, Devine S, Porter DL, Maziarz RT. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with Myelodysplastic Syndrome (MDS) or acute Myeloid Leukemia (AML): blood and marrow transplant clinical trials network. Blood. 2015;126(23):abstr LBA-8.

13.

Speziali C, Daly A, Abuhaleeqa M, Nitta J, Mourad J, Seftel M, et al. Fludarabine and Busulfan plus low dose TBI versus cyclophosphamide plus TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia: equivalent outcomes in a recent, large Canadian multicenter cohort. Blood. 2016;128(22):abstr 663.

14.

Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162(1):25–39. CrossRefPubMed

15.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia. 2017; doi: 10.1038/leu.2017.16. PubMed

16.

Roex MC, Van Balen P, Hageman L, Van Egmond E, Veld S, Hoogstraten C, et al. Prevention of viral infections after T cell depleted allogeneic stem cell transplantation by infusion of multi-antigen specific T cell products. Blood. 2016;128(22):abstr 1228.

17.

Wallhult E, Kenyon M, Liptrott S, Mank A, Ni Chonghaile M, Babic A, et al. Management of veno-occlusive disease: the multidisciplinary approach to care. Eur J Haematol. 2017;98(4):322–9. CrossRefPubMed

18.

Strouse C, Zhan Y, Zhang MJ, DiGilio A, Pasquini MC, Horowitz M, et al. Stratification of allogeneic hematopoietic cell transplant by risk of developing veno-occlusive disease: a model for assigning a risk score. Blood. 2016;128(22):abstr 983.

19.

Schuster S, Svoboda J, Nasta S, Porter DE, Chong EA, Landsburg DJ, et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126(23):abstr 183.

20.

Neelapu S, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, et al. Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1. Blood. 2016;128(22):abstr LB-A 6.

21.

Chapuis A, Egan D, Bar B, Schmitt TM, McAfee M, Perdicchio M, et al. EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML. Blood. 2016;128(22):abstr 1001.

22.

Stadtmauer M, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, et al. Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). Blood. 2016;128(22):abstr LBA-1.

23.

Le Gouill SS, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 Lyma trial of the Lysa/Goelams group. Blood. 2016;128(22):abstr 145.

24.

Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, et al. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplant. 2017;52(2):201–8. CrossRefPubMed

25.

Yu J, Storer BE, Kushekhar K, Abu ZM, Zhang Q, Gafken PR, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34(22):2583–90. CrossRefPubMed

Titel: Hematopoietic stem cell transplantation: up-date from ASH 2016
Autor:: MD Georg Hopfinger
Publikationsdatum: 01.06.2017
DOI: https://doi.org/10.1007/s12254-017-0337-1
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

ASH Meeting 2016: developments in hemostaseology

Primary signet cell carcinoma of the prostate: a case report

Post San Antonio Breast Cancer Symposium

Notes from California – experts review the ASH meeting 2016 in San Diego

Orbito-maxillofacial mesenchymal chondrosarcoma with intracranial invasion and lung metastasis

Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel